Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,862 Shares
05:26am, Tuesday, 21'st Apr 2026
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) insider Nicole Sweeny sold 1,862 shares of the firm's stock in a transaction on Friday, April 17th. The shares were sold at an average p
KalVista Pharmaceuticals (NASDAQ:KALV) CFO Brian Piekos Sells 1,862 Shares of Stock
05:26am, Tuesday, 21'st Apr 2026
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) CFO Brian Piekos sold 1,862 shares of the business's stock in a transaction on Friday, April 17th. The shares were sold at an average pr
KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach
01:05am, Saturday, 18'th Apr 2026
KalVista Pharmaceuticals (NASDAQ: KALV) CEO Ben Palleiko told investors at Needham and Company's 25th Annual Healthcare Conference that the company has seen a strong early commercial launch for EKTERL
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
07:00am, Wednesday, 08'th Apr 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive
06:11am, Tuesday, 07'th Apr 2026
KalVista Pharmaceuticals is now a commercial rare-disease play with Ekterly established as the first oral on-demand HAE therapy across seven approved markets. I think Ekterly's convenience versus inje
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 02'nd Apr 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five ne
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY® (s
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 8.7% Higher Following Analyst Upgrade
02:46am, Friday, 27'th Mar 2026
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) shot up 8.7% on Thursday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus c
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High Following Analyst Upgrade
02:46am, Friday, 27'th Mar 2026
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday after Stifel Nicolaus raised their price target on the stock f
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
02:55pm, Wednesday, 25'th Mar 2026
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
07:00am, Wednesday, 25'th Mar 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today reported financial results for the eight months ended December 31, 2025, and provided a co
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
07:00am, Friday, 20'th Mar 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted f
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
07:00am, Wednesday, 18'th Mar 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review t
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 04'th Mar 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted one new
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented at the 2026 Ameri
